We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eli Lilly and Co | NYSE:LLY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.12 | -0.15% | 770.00 | 2,785 | 13:16:22 |
From May 2019 to May 2024
By Michael Dabaie
Eli Lilly and Co. and MiNA Therapeutics Ltd. said Tuesday they are in a global research collaboration to develop novel drug candidates using MiNA's proprietary small activating RNA technology platform.
Under the terms of the agreement, MiNA will use its saRNA platform to research up to five targets selected by Lilly to address diseases across Lilly's therapeutic focus areas.
Lilly will be responsible for preclinical and clinical development of candidates and will retain exclusive commercialization rights for any products resulting from the collaboration.
MiNA will receive a $25 million upfront payment and is eligible to receive potential development and commercialization milestones up to a total of $245 million per target, as well as tiered royalties from the low-single to low-double digits on product sales.
Lilly said there would be no change to its 2021 non-GAAP earnings per share guidance as a result of this transaction.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
May 11, 2021 07:52 ET (11:52 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Eli Lilly Chart |
1 Month Eli Lilly Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
